Search - tctmd.com

Displaying 461 - 480 of 5377

Sort: Relevancy | Date

Presentation TCT 2024

TCT 262: Clinical and Hemodynamic Predictors of Stabilization and Associated Complications in Cardiogenic Shock Patients Supported With Impella 5.5

Presenter: Shashank Sinha

October 29, 2024

Presentation TCT 2024

TCT 427: Comparison of Clinical Outcomes Between Second Generation Zotarolimus- Versus Everolimus-Eluting Stents up to 10-Year Follow-up

Presenter: Woo Jin Ahn

October 29, 2024

Presentation TCT 2024

Clinical Phenotypes of TR Patients: Same but Different?

Presenter: Laura Davidson

October 29, 2024

Presentation TCT 2024

Best CLI Medical Therapy Subgroup

Presenter: Matthew Menard

October 29, 2024

Presentation TCT 2024

How Can Clinical Trials Mobilize the Diversity Efforts?

Presenter: Roxana Mehran

October 29, 2024

Presentation TCT 2024

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Presenter: Raymond Townsend

October 29, 2024

Presentation TCT 2024

Debate Con: RDN Will Ultimately Be a Niche Therapy

Presenter: Andrew Sharp

October 29, 2024

Presentation TCT 2024

Debate Con: Predictors of Efficacy are Sorely Needed in the RDN Space!

Presenter: Eric Secemsky

October 29, 2024

Presentation TCT 2024

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

Presenter: Michael Weber

October 29, 2024

Presentation TCT 2024

How to Set Up Your RDN Hypertension Program: Team Members and Patient Flow

Presenter: Michael Bloch

October 29, 2024

Presentation TCT 2024

What am I Most Anticipating in Upcoming Clinical Trials?

Presenter: Eric Secemsky

October 29, 2024

Presentation TCT 2024

What Evaluation is Required for Patient Selection for RDN?

Presenter: Naomi Fisher

October 29, 2024

Presentation TCT 2024

Reconciling Device Design and Clinical Need: How to Make TMVr Procedures Scalable and Reproducible?

Presenter: David Meerkin

October 29, 2024

Presentation TCT 2024

Most Important Clinical Trial Endpoints to the PE Clinician in the Trenches

Presenter: Behnood Bikdeli

October 29, 2024

Presentation TCT 2024

Percutaneous Treatment of Tricuspid Regurgitation with the Novel TriFlO® Device: Technology and Clinical Update

Presenter: Gian Paolo Ussia

October 29, 2024

Presentation TCT 2024

TCT 372: Clinical Outcomes Following Sirolimus-Eluting Iron Bioresorbable Scaffold Implantation: One-Year Follow-Up of the Patient-Level Pooled Analysis From the IRONMAN II and III Trials

Presenter: Lei Song

October 29, 2024

Presentation TCT 2024

TCT 370: Clinical Safety and Angiographic Performance of the Fantom Encore Bioresorbable Scaffold: Insights From an Italian Center

Presenter: Francesco Amata

October 29, 2024

Presentation TCT 2024

TCT 115: Association Between Patent Foramen Ovale Morphology and Clinical Outcomes Following Transcatheter Closure

Presenter: Lijie Sun

October 29, 2024

Presentation TCT 2024

TCT 838: Clinical Futility in Patients With Active Malignancy Undergoing Trans-Catheter Aortic Valve Replacement After Multidisciplinary Heart Team Decision

Presenter: Enrico Romagnoli

October 29, 2024

Presentation TCT 2024

TCT 841: Trends and Clinical Outcomes of TAVR in Patients With Connective Tissue Disease: A National In-Sample Database Analysis (2016-2021)

Presenter: Farah Yasmin

October 29, 2024

Advertisement

TCT 262: Clinical and Hemodynamic Predictors of Stabilization and Associated Complications in Cardiogenic Shock Patients Supported With Impella 5.5

TCT 427: Comparison of Clinical Outcomes Between Second Generation Zotarolimus- Versus Everolimus-Eluting Stents up to 10-Year Follow-up

Clinical Phenotypes of TR Patients: Same but Different?

Best CLI Medical Therapy Subgroup

How Can Clinical Trials Mobilize the Diversity Efforts?

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Debate Con: RDN Will Ultimately Be a Niche Therapy

Debate Con: Predictors of Efficacy are Sorely Needed in the RDN Space!

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

How to Set Up Your RDN Hypertension Program: Team Members and Patient Flow

What am I Most Anticipating in Upcoming Clinical Trials?

What Evaluation is Required for Patient Selection for RDN?

Reconciling Device Design and Clinical Need: How to Make TMVr Procedures Scalable and Reproducible?

Most Important Clinical Trial Endpoints to the PE Clinician in the Trenches

Percutaneous Treatment of Tricuspid Regurgitation with the Novel TriFlO® Device: Technology and Clinical Update

TCT 372: Clinical Outcomes Following Sirolimus-Eluting Iron Bioresorbable Scaffold Implantation: One-Year Follow-Up of the Patient-Level Pooled Analysis From the IRONMAN II and III Trials

TCT 370: Clinical Safety and Angiographic Performance of the Fantom Encore Bioresorbable Scaffold: Insights From an Italian Center

TCT 115: Association Between Patent Foramen Ovale Morphology and Clinical Outcomes Following Transcatheter Closure

TCT 838: Clinical Futility in Patients With Active Malignancy Undergoing Trans-Catheter Aortic Valve Replacement After Multidisciplinary Heart Team Decision

TCT 841: Trends and Clinical Outcomes of TAVR in Patients With Connective Tissue Disease: A National In-Sample Database Analysis (2016-2021)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content